We perform therapy relevant EGFR mutation detection on circulating tumor-DNA (ctDNA) from plasma of NSCLC patients using high sensitive parallel sequencing (NGS).
You are here:
Since the approval of the tyrosine kinase Inhibitor (TKI) Osimertinib for treatment of non-small cell lung cancer (NSCLC) patients with advanced tumor stage, we offer EGFR T790M mutation detection for liquid biopsies.
Liquid biopsies allow mutation detection by means of cell free, circulating tumor-DNA (ctDNA), they are minimal-invasive and can be an alternative to tissue biopsies.
⇒ Please note: Important for a reliable analysis is the information about the primary EGFR mutation (see request form)